Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression

Dysregulation of polyamine metabolism has been linked to the development of colorectal cancer (CRC), but the underlying mechanism is incompletely characterized. Here, we report that spermine synthase (SMS), a polyamine biosynthetic enzyme, is overexpressed in CRC. Targeted disruption of SMS in CRC cells results in spermidine accumulation, which inhibits FOXO3a acetylation and allows subsequent translocation to the nucleus to transcriptionally induce expression of the proapoptotic protein Bim. However, this induction is blunted by MYC-driven expression of miR-19a and miR-19b that repress Bim production. Pharmacological or genetic inhibition of MYC activity in SMS-depleted CRC cells dramatically induces Bim expression and apoptosis and causes tumor regression, but these effects are profoundly attenuated by silencing Bim. These findings uncover a key survival signal in CRC through convergent repression of Bim expression by distinct SMS- and MYC-mediated signaling pathways. Thus, combined inhibition of SMS and MYC signaling may be an effective therapy for CRC.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection Cell counts were collected using the Vi-CELL XR 2.06 (Beckman Coulter). Images were acquired by the Nikon Eclipse Ti-E inverted microscope for live imaging or Nikon A1+-Ti2 confocal microscope for immunofluorescence. Flow cytometry data were acquired on a LSR II flow cytometer (BD Biosciences). RT-PCR data were collected using a StepOne RT-PCR system (Applied Biosystems). Polyamine data were acquired by an Ultimate 3000 ultra-high performance liquid chromatography and a Q-exactive mass spectrometer (Thermo Fisher Scientific). All publicly available data referenced in our manuscript have been collected from TCGA (https://portal.gdc.cancer.gov/ projects/TCGA-COAD), GEO (https://www.ncbi.nlm.nih.gov/gds/), or the indicated websites.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The TCGA Colon Adenocarcinoma (TCGA-COAD) mRNA-sequencing data referenced during the study are available in a public repository from the GDC Data Portal (https://portal.gdc.cancer.gov/projects/TCGA-COAD). The raw microarray RNA-sequencing data "Skrzypczak Colorectal" and "Gaedcke Colorectal" are available

October 2018
from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/gds/) with accession GSE20916 and GSE20842, respectively. The corresponding processed and normalized data are available from Oncomine (https://www.oncomine.org/). The source data underlying 3a,b,4,5a,6,and 7ac,b,2a,b,d,e,f,[5][6][7]9, 10b and 11b-d are provided as a Source Data file. All the other data supporting the findings of this study are available within the article and its supplementary information files and from the corresponding author upon reasonable request.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
No statistical method was used to predetermine sample size. Sample size was chosen based on our prior studies using the same types of assays, as well as published literature, to ensure statistically significant results. In vitro studies used a standard n=3. In vivo studies were performed with 6 mice per treatment group with one tumor each, which we estimated would account for variability in tumor growth ( Data exclusions No data were excluded from the analyses.

Replication
Cell viabilty, luciferase reporter, RT-PCR, flow cytometry, immunofluorescence, polyamine, and ODC activity assays were reproduced in three independent experiments. All attempts at replication were successful. Animal studies and IHC analyses of colorectal cancer tissue microarrays were performed for a single time with biological replicates indicated in the figure legend and Methods section due to time and cost limitations.
Randomization Mice were randomized to treatment groups after they developed palpable tumors. Colorectal cancer patients' samples were randomly allocated into different groups for IHC analysis. Randomization was not relevant for other experiments, as they were performed in cell lines.

Blinding
The experiments were not blinded, except the IHC staining analysis (staining and scoring) that was done in a blinded fashion.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
"At Cell Signaling Technology (CST), we understand that there is no single assay that can determine the validity of an antibody.
Confirming that an immunoreagent is sufficiently specific and sensitive depends on the application and protocol being used, the type and quality of sample being analyzed, and the inherent biophysical properties of the antibody itself.
To ensure our antibodies will work in your experiment, we adhere to the Hallmarks of Antibody Validation™, six complementary strategies that can be used to determine the functionality, specificity, and sensitivity of an antibody in any given assay. CST adapted the work by Uhlen, et. al., ("A Proposal for Validation of Antibodies." Nature Methods (2016)) to build the Hallmarks of Antibody Validation, based on our decades of experience as an antibody manufacturer and our dedication to reproducible science."